Expression of ADAM15 in lung carcinomas

被引:43
作者
Schütz, A
Härtig, W
Wobus, M
Grosche, J
Wittekind, C
Aust, G
机构
[1] Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany
[2] Univ Leipzig, Paul Flechsig Inst Brain Res, Leipzig, Germany
[3] Univ Leipzig, Inst Anat, Leipzig, Germany
关键词
ADAM; 15; integrin; lung carcinoma;
D O I
10.1007/s00428-004-1193-z
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
ADAM15, a member of the ADAM ( a disintegrin and metalloprotease) family, is a membrane protein containing both protease and adhesion domains and may, thus, be involved in tumor invasion and metastasis. The aim of this study was to analyze the expression of ADAM15 and its potential ligand, integrin alpha v beta 3 (CD51/CD61), in lung carcinoma cell lines and tissues. Most small cell lung carcinomas (SCLCs) and non-SCLC cell lines were ADAM15, alpha v and beta 3 integrin mRNA positive. Half of the cell lines expressed ADAM15, and three expressed the alpha v beta 3 heterodimer at the cell surface as shown using flow cytometry. Paraffin sections of pulmonary epithelial tumors, including SCLCs ( n= 26), squamous cell cancer ( SCCs, n= 27) and adenocarcinomas ( ACs, n= 17) were stained with antibodies to the ectosolic and cytosolic domain of ADAM15 and alpha v beta 3 integrin complex. The results were scored ( 0 - 12, according to Remmele's score). Normal epithelial cells of the lung were negative or slightly positive for ADAM15 (score< 2). The score was always significantly higher for tumor cells. ACs showed the strongest staining ( tumor center; ADAM15ecto; mean +/- SEM; 5.47 +/- 1.04), whereas SCLCs only showed weak ADAM15 expression ( 2.67 +/- 0.42; SCCs: 3.62 +/- 0.62). Frequently, significantly stronger ADAM15 expression has been shown in tumor cells located at the front of invasion compared with those within solid formations. Overall analysis of all tumor specimens and each tumor type revealed no significant correlation between tumor stage or degree of differentiation and ADAM15 ectosolic or cytosolic domain expression in tumor cells. Both molecules are often co-localized in the same tumor cells in ADAM15- and alpha v beta 3 integrin-positive carcinomas. In summary, lung carcinoma cell lines and tissues were frequently ADAM15 positive.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 52 条
[1]   DNA vaccination: Transfection and activation of dendritic cells as key events for immunity [J].
Akbari, O ;
Panjwani, N ;
Garcia, S ;
Tascon, R ;
Lowrie, D ;
Stockinger, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (01) :169-177
[2]   Establishment of a clonal cell line producing granulocyte colony-stimulating factor and parathyroid hormone-related protein from a lung cancer patient with leukocytosis and hypercalcemia [J].
Asahi, Y ;
Kubonishi, I ;
Imamura, J ;
Kamioka, M ;
Matsushita, H ;
Furihata, M ;
Ohtsuki, Y ;
Miyoshi, I .
JAPANESE JOURNAL OF CANCER RESEARCH, 1996, 87 (05) :451-458
[3]   CHARACTERIZATION OF THE STATE OF DIFFERENTIATION OF 6 NEWLY ESTABLISHED HUMAN NON-SMALL-CELL LUNG-CANCER CELL-LINES [J].
BEPLER, G ;
KOEHLER, A ;
KIEFER, P ;
HAVEMANN, K ;
BEISENHERZ, K ;
JAQUES, G ;
GROPP, C ;
HAEDER, M .
DIFFERENTIATION, 1988, 37 (02) :158-171
[4]  
Böhm BB, 1999, ARTHRITIS RHEUM, V42, P1946, DOI 10.1002/1529-0131(199909)42:9<1946::AID-ANR21>3.0.CO
[5]  
2-E
[6]  
Böhm BB, 2001, ARTHRITIS RHEUM-US, V44, P2046, DOI 10.1002/1529-0131(200109)44:9<2046::AID-ART354>3.0.CO
[7]  
2-3
[8]   Nuclear overexpression of the oncoprotein β-catenin in colorectal cancer is localized predominantly at the invasion front [J].
Brabletz, T ;
Jung, A ;
Hermann, K ;
Gunther, K ;
Hohenberger, W ;
Kirchner, T .
PATHOLOGY RESEARCH AND PRACTICE, 1998, 194 (10) :701-704
[9]   β-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer [J].
Brabletz, T ;
Jung, A ;
Dag, S ;
Hlubek, F ;
Kirchner, T .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (04) :1033-1038
[10]   Integrin dependent migration of lung cancer cells to extracellular matrix components [J].
Bredin, CG ;
Sundqvist, KG ;
Hauzenberger, D ;
Klominek, J .
EUROPEAN RESPIRATORY JOURNAL, 1998, 11 (02) :400-407